Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Literature DB >> 28284917

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Jordi Bruix¹, Maria Reig², Bruno Sangro³.

Abstract

Entities: Chemical

Mesh：

Year: 2017 PMID： 28284917 DOI： 10.1016/j.jhep.2017.02.032

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT.

Authors: Manuel de la Torre-Aláez; Carlota Jordán-Iborra; Andrea Casadei-Gardini; José Ignacio Bilbao; Macarena Rodriguez-Fraile; Lidia Sancho; Delia D'Avola; José Ignacio Herrero; Mercedes Iñarrairaegui; Bruno Sangro
Journal: Cardiovasc Intervent Radiol Date: 2020-03-12 Impact factor: 2.740

Review 2. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.

Authors: Francesco Tovoli; Matteo Renzulli; Alessandro Granito; Rita Golfieri; Luigi Bolondi
Journal: Hepat Oncol Date: 2017-11-17

3. A Matter of TACEte: Plain Vanilla or Combination?

Authors: David E Kaplan
Journal: Dig Dis Sci Date: 2020-04 Impact factor: 3.199

4. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Authors: Alexander Gerbes; Fabien Zoulim; Herbert Tilg; Jean-François Dufour; Jordi Bruix; Valérie Paradis; Riad Salem; Markus Peck-Radosavljevic; Peter R Galle; Tim F Greten; Jean-Charles Nault; Matias A Avila
Journal: Gut Date: 2017-11-17 Impact factor: 23.059

5. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.

Authors: Francesco Tovoli; Matteo Renzulli; Giulia Negrini; Stefano Brocchi; Alessia Ferrarini; Andrea Andreone; Francesca Benevento; Rita Golfieri; Antonio Maria Morselli-Labate; Marianna Mastroroberto; Radu Ion Badea; Fabio Piscaglia
Journal: Eur Radiol Date: 2018-04-09 Impact factor: 5.315

6. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

Authors: Ruwanthi Kolamunnage-Dona; Sarah Berhane; Harry Potts; Edward H Williams; James Tanner; Tobias Janowitz; Matthew Hoare; Philip Johnson
Journal: J Hepatol Date: 2021-05-27 Impact factor: 30.083

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

1. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT.

Review 2. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.

3. A Matter of TACEte: Plain Vanilla or Combination?

4. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

5. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.

6. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.

Review 7. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.

Review 8. Controversies in the management of hepatocellular carcinoma.

Review 9. Insights into the success and failure of systemic therapy for hepatocellular carcinoma.

Review 10. Systemic Treatment Options in Hepatocellular Carcinoma.